Analyst Bullish on Pelthos Therapeutics: Big Potential in Skin Treatment
Piper Sandler starts coverage on Pelthos Therapeutics with Overweight rating and $48 price target, highlighting ZELSUVMI as a promising new treatment for common viral skin infection molluscum contagiosum with peak U.S. sales potentially over $200M.